Investigate / reported ownership
BSX
Boston Scientific Corp
6 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.
Who reports owning BSX?
Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.
| #↑ | Manager | % Port. | History | Value | Shares |
|---|---|---|---|---|---|
| 1 | Lee Ainslie | 2.3% | 12q | $253M | 5,937,553 |
| 2 | Joel Greenblatt | 0.1% | 40q | $213M | 4,987,748 |
| 3 | Sarah Ketterer | 0.3% | — 1q | $31M | 720,339 |
| 4 | Dodge & Cox Funds | <0.1% | 40q | $4M | 87,485 |
| 5 | Mairs & Power Funds | <0.1% | 20q | $423K | 9,914 |
Go beyond ownership.
Boston Scientific develops, manufactures and markets medical devices that physicians use to diagnose and treat conditions, offering less-invasive alternatives to surgery and other traumatic procedures.
Question to investigate: Can Boston Scientific keep launching competitive next-generation products across its businesses while competition, pricing pressure and trade uncertainty persist?
Company research reviewed 2026-10-02; a dated source-linked starting point, not the investors’ stated reasons.
Understand the business and investment case →Filing dates and original SEC sources
Reported position changes
Net disclosed share changes—not individual trades or execution dates. NEW has no prior-position percentage comparison; EXIT weight refers to the previous report.
| Manager | Move | % Port. | Δ Shares | Value | Filed |
|---|---|---|---|---|---|
| Stephen Mandel | EXIT | 0.1% | -100% | $0 | Aug 14, 2026 |
Keep your next step small.
Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.
Record my own view →Optional email follow
Latticework Follow
Follow BSX
Email me only when a reviewed weekly edition contains a material new decision about BSX: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.
Confirm by email. Manage or stop follows in one click. See our privacy notice.
Long US 13F disclosures omit shorts and can be amended. CUSIP 101137107. No current price, valuation or manager motive is inferred.